Treatment of progressive multiple sclerosis: Challenges and promising perspectives
Author:
- 1 June 2018
- journal article
- review article
- Published by Elsevier in Revue Neurologique
- Vol. 174 (6) , 441-448
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 studyThe Lancet, 2018
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisNew England Journal of Medicine, 2017
- Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisPLOS ONE, 2017
- Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialThe Lancet, 2016
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology, 2014
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MSMultiple Sclerosis Journal, 2012
- Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialThe Lancet, 2002
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisThe Lancet, 1998
- Rating neurologic impairment in multiple sclerosisNeurology, 1983